Treatment of Menorrhagia with Intrauterine Release of Progesterone
Overview
Authors
Affiliations
In 12 women with menorrhagia (greater than or equal to 80 ml per menstrual period) a progesterone-releasing device (Progestasert) was inserted. The women were followed by repeated measurements of the blood loss for 12 periods. The menstrual blood loss was significantly reduced after 1 month but the duration of bleeding was somewhat prolonged. Twelve months after insertion the menstrual blood loss amounted to 35% of the blood loss before the insertion. The Progestasert is a valuable treatment for menorrhagia.
Progestogen-releasing intrauterine systems for heavy menstrual bleeding.
Bofill Rodriguez M, Lethaby A, Jordan V Cochrane Database Syst Rev. 2020; 6:CD002126.
PMID: 32529637 PMC: 7388184. DOI: 10.1002/14651858.CD002126.pub4.
Benefits and risks of pharmacological agents used for the treatment of menorrhagia.
Roy S, Bhattacharya S Drug Saf. 2004; 27(2):75-90.
PMID: 14717620 DOI: 10.2165/00002018-200427020-00001.
Magos A BMJ. 1990; 300(6739):1537-8.
PMID: 2196953 PMC: 1663113. DOI: 10.1136/bmj.300.6739.1537.
Risk-benefit assessment of drugs used for the treatment of menstrual disorders.
Higham J, Shaw R Drug Saf. 1991; 6(3):183-91.
PMID: 1905938 DOI: 10.2165/00002018-199106030-00004.